Switch theme
Sign up to access all valuation multiples
Boule Diagnostics AB is a company operating in the diagnostics market. It is engaged in the development, manufacturing and marketing instruments and consumables for blood diagnostics. The firm focuses on the decentralized market segment. The systems are intended for small and medium-sized hospitals, clinics and laboratories within outpatient care. Through its subsidiaries, the Group operates in Sweden, USA, and China.
1996
212
LTM Revenue $56.3M
LTM EBITDA -$17.0M
$50.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Boule Diagnostics has a last 12-month revenue (LTM) of $56.3M and a last 12-month EBITDA of -$17.0M.
In the most recent fiscal year, Boule Diagnostics achieved revenue of $57.6M and an EBITDA of -$33.6M.
Boule Diagnostics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Boule Diagnostics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $56.3M | XXX | $57.6M | XXX | XXX | XXX |
| Gross Profit | $25.8M | XXX | $26.0M | XXX | XXX | XXX |
| Gross Margin | 46% | XXX | 45% | XXX | XXX | XXX |
| EBITDA | -$17.0M | XXX | -$33.6M | XXX | XXX | XXX |
| EBITDA Margin | -30% | XXX | -58% | XXX | XXX | XXX |
| EBIT | $6.7M | XXX | -$30.5M | XXX | XXX | XXX |
| EBIT Margin | 12% | XXX | -53% | XXX | XXX | XXX |
| Net Profit | -$18.1M | XXX | -$30.6M | XXX | XXX | XXX |
| Net Margin | -32% | XXX | -53% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $16.3M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Boule Diagnostics's stock price is SEK 8 (or $1).
Boule Diagnostics has current market cap of SEK 310M (or $32.0M), and EV of SEK 491M (or $50.6M).
See Boule Diagnostics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $50.6M | $32.0M | XXX | XXX | XXX | XXX | $0.20 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Boule Diagnostics has market cap of $32.0M and EV of $50.6M.
Boule Diagnostics's trades at 0.9x EV/Revenue multiple, and -1.5x EV/EBITDA.
Equity research analysts estimate Boule Diagnostics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Boule Diagnostics has a P/E ratio of -1.8x.
See valuation multiples for Boule Diagnostics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $32.0M | XXX | $32.0M | XXX | XXX | XXX |
| EV (current) | $50.6M | XXX | $50.6M | XXX | XXX | XXX |
| EV/Revenue | 0.9x | XXX | 0.9x | XXX | XXX | XXX |
| EV/EBITDA | -3.0x | XXX | -1.5x | XXX | XXX | XXX |
| EV/EBIT | 7.6x | XXX | -1.7x | XXX | XXX | XXX |
| EV/Gross Profit | 2.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.8x | XXX | -1.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -12.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBoule Diagnostics's last 12 month revenue growth is -1%
Boule Diagnostics's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.3M for the same period.
Boule Diagnostics's rule of 40 is 11% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Boule Diagnostics's rule of X is -32% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Boule Diagnostics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -1% | XXX | 0% | XXX | XXX | XXX |
| EBITDA Margin | -30% | XXX | -58% | XXX | XXX | XXX |
| EBITDA Growth | -147% | XXX | -3% | XXX | XXX | XXX |
| Rule of 40 | 11% | XXX | -59% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -32% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 21% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 72% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 98% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Boule Diagnostics acquired XXX companies to date.
Last acquisition by Boule Diagnostics was XXXXXXXX, XXXXX XXXXX XXXXXX . Boule Diagnostics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Boule Diagnostics founded? | Boule Diagnostics was founded in 1996. |
| Where is Boule Diagnostics headquartered? | Boule Diagnostics is headquartered in Sweden. |
| How many employees does Boule Diagnostics have? | As of today, Boule Diagnostics has 212 employees. |
| Who is the CEO of Boule Diagnostics? | Boule Diagnostics's CEO is Mr. Torben Nielsen. |
| Is Boule Diagnostics publicy listed? | Yes, Boule Diagnostics is a public company listed on STO. |
| What is the stock symbol of Boule Diagnostics? | Boule Diagnostics trades under BOUL ticker. |
| When did Boule Diagnostics go public? | Boule Diagnostics went public in 2011. |
| Who are competitors of Boule Diagnostics? | Similar companies to Boule Diagnostics include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Boule Diagnostics? | Boule Diagnostics's current market cap is $32.0M |
| What is the current revenue of Boule Diagnostics? | Boule Diagnostics's last 12 months revenue is $56.3M. |
| What is the current revenue growth of Boule Diagnostics? | Boule Diagnostics revenue growth (NTM/LTM) is -1%. |
| What is the current EV/Revenue multiple of Boule Diagnostics? | Current revenue multiple of Boule Diagnostics is 0.9x. |
| Is Boule Diagnostics profitable? | Yes, Boule Diagnostics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Boule Diagnostics? | Boule Diagnostics's last 12 months EBITDA is -$17.0M. |
| What is Boule Diagnostics's EBITDA margin? | Boule Diagnostics's last 12 months EBITDA margin is -30%. |
| What is the current EV/EBITDA multiple of Boule Diagnostics? | Current EBITDA multiple of Boule Diagnostics is -3.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
